Haemonetics Corporation stocks have been trading up by 15.96 percent after strong earnings and robust blood-management demand boosted sentiment.
Click Here for a Millionaire's POV on Trading HAE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Citigroup upgraded Haemonetics from Neutral to Buy and lifted its price target to $123, well above the current analyst mean target of $108.40.
- Shares of HAE jumped about 2.4% after the Citi upgrade and target hike from $92 to $123, signaling traders are leaning into the bullish call.
- Citi is banking on earnings upside from Haemonetics’ new non-exclusive CSL supply agreement, estimating every 10% share recapture adds $0.13 to EPS.
- The Vivasure deal hit a $6.1M milestone payment to Orchestra BioMed, completing $11M up front and setting up up to $10M in future earnouts.
- Haemonetics will report Q2 FY2027 results on 2026/11/05, a key checkpoint for traders watching the CSL and Vivasure stories unfold.
Live Update At 12:32:46 EDT: On Thursday, October 08, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 15.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
HAE has quietly been grinding higher, and the recent tape backs that up. For weeks, Haemonetics traded mostly in a tight $103–$110 band. Then the Citi upgrade hit, and HAE exploded from a prior close near $101.71 to finish at $117.94, with an intraday high at $121. That is a sharp expansion in range and a clear shift in momentum.
Under the hood, Haemonetics is a classic high‑margin medical tech name. Gross margin sits around 59%, which gives HAE plenty of cushion to fund R&D and deals like Vivasure while still driving earnings. Over the last quarter reported (ending 2026/06/27), revenue came in near $339M with net income of about $33M, implying a profit margin a bit above 9% for the quarter and roughly 7% on a trailing basis.
More Breaking News
- RIOT Stock Slides As Traders Study Key Support
- ITUB Stock Grinds Higher As Bulls Defend New Price Zone
- SPCX Stock Holds Gains As AI Scrutiny Narrative Builds
- WULF Stock Slips As Insider Files Form 144 Sale Notice
HAE is not cheap on traditional metrics. The P/E around 50 and price‑to‑sales near 3.5 tell traders they are paying up for growth and execution. But leverage looks manageable, with a current ratio at 3.1 and interest coverage north of 20 times. For active traders, that mix — strong margins, decent balance sheet, premium valuation, and now a catalyst‑driven breakout — sets the stage for more volatile trading in both directions.
Why Traders Are Watching Haemonetics Now
The near‑term story for HAE is all about the Street waking up to new earnings power. Citigroup moved Haemonetics from Neutral to Buy and pushed its price target to $123. That is not only well above the prior $92 target; it also sits meaningfully above the current analyst mean target of $108.40. When a major bank steps out ahead of consensus like that, momentum traders pay attention.
The upgrade hangs on hard numbers, not vague promises. Citi pointed to a new non‑exclusive supply agreement with CSL and laid out the math: every 10% share HAE wins back in that business adds about $0.13 to EPS. For traders, that is gold — it turns a headline about “supply agreements” into a clear, tradable earnings lever. If Haemonetics executes, EPS has room to ramp without a full reinvention of the company.
The price action backed this up. After the call, HAE climbed roughly 2.4%, trading around $108 before stretching into the high teens and tagging $121 intraday. Interestingly, that move came on volume below the daily average. Lower‑than‑usual volume on an upside reaction often means there are still plenty of sidelined traders who have not repositioned yet. If more funds decide to follow Citi’s lead, HAE can see further legs — but it also means late chasers must be disciplined with risk.
At the same time, Haemonetics is still digesting its Vivasure acquisition. The company just triggered a $6.1M milestone payment to Orchestra BioMed, taking total paid consideration to $11M, with up to $10M more tied to future Vivasure‑related revenue. The milestone confirms progress on Vivasure’s PerQseal Elite vessel closure system is tracking to plan. For HAE, that is another potential growth engine, but it does come with contingent cash obligations traders should track.
Add in the newly announced Q2 FY2027 earnings date on 2026/11/05, and HAE now has a loaded catalyst calendar that short‑term traders can trade around.
Conclusion
Right now, Haemonetics sits at the crossroads of strong technical momentum and fresh fundamental catalysts. HAE’s chart shows a clean breakout from months of range‑bound trading, powered by the Citi upgrade and a higher $123 price target. Underneath, the balance sheet and margins look solid enough to support a premium valuation, while the CSL supply deal and Vivasure integration offer concrete paths to higher future earnings.
For active traders, the key is treating HAE like any other fast‑moving catalyst stock: respect the volatility, map your levels, and plan exits before entries. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” The 2.4% pop on sub‑average volume suggests the trade is not crowded yet, but that can change fast if more firms echo Citigroup’s bullish stance on Haemonetics.
The upcoming 2026/11/05 earnings call will be critical. Traders will want to hear how management frames the CSL opportunity, how quickly Vivasure’s PerQseal Elite can ramp, and whether margins stay intact as Haemonetics spends on growth. Any concrete EPS guidance tied to these drivers could reset expectations again.
As Tim Sykes likes to say, “The market rewards preparation, not prediction.” With HAE, that means studying the chart, understanding the CSL and Vivasure numbers, and coming into each trading day with a clear plan — not a hope. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.